Correction: Titmuss et al. Immune Activation Following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. Int. J. Mol. Sci. 2023, 24, 5869

E Titmuss¹, K Milne², M R Jones¹, T Ng³, J T Topham⁴, S D Brown¹, D F Schaeffer⁴, S Kalloger³, D Wilson⁵, R D Corbett¹, L M Williamson¹, K Mungall¹, A J Mungall¹, R A Holt^{1

6}, B H Nelson^{2

6}, S J M Jones¹, J Laskin⁵, H J Lim⁵, M A Marra^{1

6}

Affiliations

¹ Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC V5Z 4S6, Canada.
² Deeley Research Centre, BC Cancer, Victoria, BC V8R 6V5, Canada.
³ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada.
⁴ Pancreas Centre BC, Vancouver, BC V5Z 1G1, Canada.
⁵ Department of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada.
⁶ Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z2, Canada.

PMID: 39596550
PMCID: PMC11594758
DOI: 10.3390/ijms252212225

Published Erratum

Correction: Titmuss et al. Immune Activation Following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. Int. J. Mol. Sci. 2023, 24, 5869

E Titmuss et al. Int J Mol Sci. 2024.

. 2024 Nov 14;25(22):12225.

doi: 10.3390/ijms252212225.

Authors

Affiliations

¹ Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, BC V5Z 4S6, Canada.
² Deeley Research Centre, BC Cancer, Victoria, BC V8R 6V5, Canada.
³ Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 1Z7, Canada.
⁴ Pancreas Centre BC, Vancouver, BC V5Z 1G1, Canada.
⁵ Department of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada.
⁶ Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 1Z2, Canada.

PMID: 39596550
PMCID: PMC11594758
DOI: 10.3390/ijms252212225

Abstract

The journal's Editorial Office and Editorial Board are jointly issuing a resolution and removal of the Journal Notice linked to this article [...].

PubMed Disclaimer

Erratum for

Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study.
Titmuss E, Milne K, Jones MR, Ng T, Topham JT, Brown SD, Schaeffer DF, Kalloger S, Wilson D, Corbett RD, Williamson LM, Mungall K, Mungall AJ, Holt RA, Nelson BH, Jones SJM, Laskin J, Lim HJ, Marra MA. Titmuss E, et al. Int J Mol Sci. 2023 Mar 20;24(6):5869. doi: 10.3390/ijms24065869. Int J Mol Sci. 2023. PMID: 36982943 Free PMC article.

References

1. Titmuss E., Milne K., Jones M.R., Ng T., Topham J.T., Brown S.D., Schaeffer D.F., Kalloger S., Wilson D., Corbett R.D., et al. Immune Activation Following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. Int. J. Mol. Sci. 2023;24:5869. doi: 10.3390/ijms24065869. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- MDPI
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: Titmuss et al. Immune Activation Following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. Int. J. Mol. Sci. 2023, 24, 5869

Affiliations

Correction: Titmuss et al. Immune Activation Following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study. Int. J. Mol. Sci. 2023, 24, 5869

Authors

Affiliations

Abstract

Erratum for

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources

Abstract

Erratum for

Similar articles

References

Publication types

Related information

LinkOut - more resources

Full Text Sources